Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III

Second Drug Is Market’s First Intranasal CGRP Inhibitor

 
• By Mandy Jackson
  
Young female student with headache
Ultra-rapid onset in as soon as 15 minutes could keep migraine patients from leaving school or work • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D